Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Dr. Mukherjee on the Role of Disease Biology in the Treatment of MCL

February 14th 2023

Akash Mukherjee, MD, discusses the importance of understanding disease biology when attempting to individualize treatment approaches in mantle cell lymphoma.

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13th 2023

The combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cell lymphoma, according to preliminary findings from the phase 2b VITALIZE trial.

CAR T-Cell Therapy for Patients With R/R FL

February 13th 2023

A discussion on which patients with relapsed/refractory follicular lymphoma are good candidates for CAR T-cell therapy.

Available Treatment Options for Relapsed/Refractory Follicular Lymphoma (R/R FL)

February 13th 2023

Dr Marc S Hoffman reviews the currently available treatment options for relapsed/refractory follicular lymphoma.

Dr. Linhares on Patient-Reported Outcomes From the OUTREACH Trial in R/R LBCL

February 10th 2023

Yuliya Linhares, MD, discusses the trial design, methodology, and key efficacy and safety results from the phase 2 OUTREACH trial (NCT03744676) evaluating lisocabtagene maraleucel (liso-cel; Breyanzi) in relapsed/refractory large B-Cell lymphoma (LBCL).

Dr. Perez Perez on Results From a Retrospective Study of Polatuzumab Regimens in R/R LBCL

February 10th 2023

Ariel Perez Perez, MD, discusses key results and clinical implications from a retrospective study of polatuzumab-vedotin plus rituximab with or without bendamustine in relapsed/refractory large B-cell lymphomas.

Intermittent Dosing Schedule of MDM2 Inhibitor Appears Tolerable in Advanced Cancers

February 8th 2023

The selective small molecule MDM2 inhibitor milademetan administered at an intermittent dosing schedule was tolerable and showed early efficacy in patients with advanced cancers, according to findings from a phase 1 study.

Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL

February 7th 2023

Marc S. Hoffman, MD, explains how to select the appropriate CAR T-cell therapy for each patient, and the barriers patients with R/R LBCL face in receiving CAR T-cell therapy, despite its high efficacy rate.

Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?

February 7th 2023

Experts discuss data on a novel form of CAR T-cell therapy, rapcabtagene autoleucel, for the second-line treatment of R/R LBCL with a faster manufacturing process.

Frontline Pola-R-CHP, CAR T-Cell Second-line Therapies Are Not Cost-effective in DLBCL

February 7th 2023

An economic analysis showed that neither polatuzumab vedotin-piiq added to standard of care chemotherapy nor CD19-directed chimeric antigen receptor T-cell therapy is likely to be the most cost-effective for patients with diffuse large B-cell lymphoma.

Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCL

February 2nd 2023

Closing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.

Treatment Sequencing in LBCL: Clinical Trial and Real-World Data

February 2nd 2023

Experts discuss the role of clinical and real-world data in informing treatment sequencing in patients with large B-cell lymphoma (LBCL) in the academic and community setting,

Additional Key Data Updates from ASH 2022 on Treatment of LBCL

February 2nd 2023

Experts highlight additional data updates from the ASH 2022 annual meeting regarding the treatment of patients with LBCL.

Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCL

February 2nd 2023

Dr Lunning, DO, FACP, shares his impressions on the toxicity profile of axi-cel and liso-cel, and how he approaches treatment decision making for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

CAR T-Cell Therapy as Second-Line Treatment in LBCL

February 2nd 2023

Matthew Lunning, DO, FACP, discusses the role of CAR T-cell therapy in the second-line treatment of large B-cell lymphoma (LBCL).

ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL

January 30th 2023

Loretta J. Nastoupil, MD, reviews data from the ZUMA-7 trial investigating the use of axicabtagene ciloleucel as a second-line therapy for large b-cell lymphoma.

Magrolimab Plus Rituximab/Chemo Elicits Deep Responses in Relapsed/Refractory DLBCL

January 28th 2023

The combination of magrolimab, rituximab, gemcitabine, and oxaliplatin produced deep, durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma.

Treatment Strategies for Patients with R/R LBCL

January 24th 2023

Experts provide their perspective on the treatment landscape for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

CAR T-Cell Therapy in R/R LBCL: TRANSFORM, ZUMA-7, and PILOT Studies

January 24th 2023

In the context of CAR T-cell therapy, Manali Kamdar, MD, reviews TRANSFORM, ZUMA-7, and PILOT trials in the treatment of patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

Overview of Large B-Cell Lymphoma (LBCL)

January 24th 2023

Experts discuss Large B-Cell Lymphoma (LBCL) and treatment strategies for patients with LBCL.